RVNC Revance Therapeutics Inc
2,776
$3.16
$0.14
(4.64%)
| Watchers | 2,776 |
| 52-Wk Low | $3.00 |
| 52-Wk High | $33.10 |
| Market Cap | $315.43M |
| Volume | 2.47M |
| 52-Wk High | $33.10 |
| 52-Wk Low | $3.00 |
Revance Reports First Quarter 2024 Financial Results, Provides Corporate UpdateBusiness Wire • 11 days ago
Revance Therapeutics, Inc. (NASDAQ: RVNC), today reported financial results for the first quarter ended March 31, 2024 and provided a corporate update. Financial Highlights In connection with the...
Share to Feed
Revance Therapeutics, Inc. (NASDAQ: RVNC), today announced that the company will release first quarter 2024 financial results on Thursday, May 9, 2024, after the close of market. Revance will host a...
Revance Therapeutics, Inc. (NASDAQ: RVNC), today announced two poster presentations on DAXXIFY for the treatment of cervical dystonia at the annual meeting of American Academy of Neurology (AAN...
For the last three days, A.I.dvisor has detected that RVNC's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...
Revance Therapeutics, Inc. (NASDAQ: RVNC) today announced new hire grants totaling an aggregate of 222,452 inducement restricted stock units (RSUs) to 29 employees. The RSUs vest over four years...
This is a signal that RVNC's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options...
This is a Bearish indicator signaling RVNC's price could decline from here. Traders may explore shorting the stock or put options...
This indicator may be signaling that RVNC's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...
Revance Therapeutics, Inc. (NASDAQ:RVNC Get Free Report) shares were down 3.8% on Tuesday . The company traded as low as $5.92 and last traded at $6.02. Approximately 159,732 shares changed...
Revance Therapeutics, Inc. (NASDAQ:RVNC Get Free Report) has received an average recommendation of Moderate Buy from the eight ratings firms that are currently covering the...